Key result
Tirzepatide increases mean blood pressure by ~24 mmHg vs. vehicle in hypertensive rat models.
Why the study?
Does tirzepatide reduce blood pressure in hypertensive rats without diabetes or obesity?
Does tirzepatide reduce blood pressure in hypertensive rats without diabetes or obesity?
Answers are grounded in this paper and cite their sources.
In a preclinical model of hypertension without diabetes or obesity, tirzepatide paradoxically increased blood pressure and sympathetic nervous system activity, suggesting its clinical blood pressure-lowering effects may be primarily driven by weight loss.
Background We have demonstrated that sympathetic nerve activity is regulated by central sympathetic output, and that sympathetic overactivation contributes to the pathophysiology of hypertension. Recently, tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GIP/GLP-1) receptor agonist, has been shown to reduce blood pressure, as well as body weight, in patients with type 2 diabetes mellitus and/or obesity. However, the direct effects of GIP/GLP-1 receptor agonist on blood pressure and sympathetic output in hypertension without type 2 diabetes mellitus or obesity remains unclear. Purpose This study aimed to investigate the impact of tirzepatide on blood pressure and sympathetic output from the brain in hypertensive rats without diabetes or obesity. Methods Seven-week-old male stroke-prone spontaneously hypertensive rats (SHRSP) were used. On Day 1, a telemetry device was implanted to measure blood pressure and heart rate. From Day 7 onwards, tirzepatide (25 nmol/kg, subcutaneously, every two days) or vehicle was administered for four weeks. On Day 35, physiological, cardiovascular, and sympathetic nervous system parameters were assessed. Results Mean blood pressure was significantly higher in the tirzepatide-treated group compared to the vehicle-treated group (206.2 ± 5.0 vs. 182.1 ± 7.0 mmHg, p = 0.026, n = 8 vs. n = 6; Figure 1), whereas heart rate showed no significant difference (322.7 ± 5.7 vs. 308.2 ± 6.3 bpm, p = 0.24). Body weight and food intake were significantly lower in the tirzepatide group than in the vehicle group (body weight: 242.4 ± 11.7 vs. 275.8 ± 2.0 g, p = 0.048; food intake: 440.9 ± 22.7 vs. 516.7 ± 7.0 g/4 weeks, p = 0.019). However, there were no significant differences in heart weight/tibia length, lung weight/tibia length, or echocardiographic parameters. Notably, neuronal activity in the rostral ventrolateral medulla (RVLM), which reflects sympathetic output, was significantly higher in the tirzepatide group than in the vehicle group, as assessed by c-Fos expression in immunohistochemical staining. Conclusions and Perspectives Contrary to our expectations, tirzepatide enhanced sympathetic nervous system activity, leading to further increases in blood pressure in hypertensive rats. These findings suggest that the blood pressure-lowering effect of tirzepatide observed in obese individuals may be primarily attributed to weight loss.
No takes yet. Share an insight, caveat, or question.
Ono et al. (2025) studied Hypertension without diabetes or obesity (n=14). Tirzepatide vs. Vehicle was evaluated on Mean blood pressure (p=0.026). Tirzepatide increased mean blood pressure compared to vehicle in stroke-prone spontaneously hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: